7 months ago
Sigachi Develops New Cystic Fibrosis APIs
Sigachi Industries, a pharmaceutical company, has created a new mix of medicines called APIs for treating Cystic Fibrosis.
This mix includes three special ingredients: Vanzacaftor, Tezacaftor, and Deutivacaftor.
The company thinks this new mix could make them around ₹250 crore every year starting from the fourth quarter of 2026-27.
This is a big deal because the global market for Cystic Fibrosis treatments is expected to grow a lot.
The company's stock price went up a bit after this news, but some experts think it might still have a hard time.
The company is also working on other important medicines and plans to keep growing.
Sigachi Industries developed a new API combination for Cystic Fibrosis, including Vanzacaftor, Tezacaftor, and Deutivacaftor.
The company projects a revenue potential of ₹250 crore per year starting from Q4 of FY2026-27.
The global market for cystic fibrosis therapeutics is projected to surpass USD 10 billion.
Vanzacaftor's patent protection extends until 2039, providing long-term revenue stability.
Sigachi Industries' stock price rebounded from its intraday low but may remain under pressure according to analysts.
- Who
- Sigachi Industries
- What
- Developed new API combination for Cystic Fibrosis
- Where
- Hyderabad, India
- When
- Wednesday, January 21, 2026
- Why
- To expand presence in complex, high-value specialty APIs and drive growth
Key facts
- Company
- Sigachi Industries
- API Combination
- Vanzacaftor, Tezacaftor, Deutivacaftor
- Revenue Potential
- ₹250 crore per year
- Market Projection
- Global CF therapeutics market to surpass USD 10 billion
- Patent Protection
- Vanzacaftor patent extends until 2039
- Stock Performance
- Opened at ₹23.69, intraday low ₹23.46, high ₹24.53
- Analyst View
- Stock likely to remain under pressure, next support at ₹21
Quotes
Lijo Chacko
Deputy Group CEO, Sigachi Industries
“This milestone reflects Sigachi’s focused strategy of building depth in complex and differentiated APIs with long-term growth visibility. Our continued investments in R&D and partnerships are aimed at strengthening our position in high-entry-barrier specialty segments and creating sustainable value for stakeholders.”
thehindubusinessline.com
